Accountability in Opioid Advertising Act
This bill requires the Food and Drug Administration to prioritize the review of advertising and other promotional materials for drug for serious, life-threatening diseases or conditions or substance use disorders, especially opioids (drugs with effects similar to opium, such as certain pain medications)and drugs used in the treatment of opioid use disorders.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.